Investment Rating - The investment rating for the company is "Buy" and is maintained [2] Core Insights - The company reported a revenue of 249 million yuan for the first three quarters of 2025, representing a year-on-year growth of 30.53%. The net profit attributable to the parent company was 76 million yuan, up 43.65% year-on-year [5] - The company plans to acquire 100% of Easy Medical for 335 million yuan, which is expected to broaden its market potential [6] - The company has secured exclusive agency agreements for various medical products, which are anticipated to enhance revenue and profit further [7] Financial Performance - For Q3 2025, the company achieved a revenue of 91 million yuan, a 32.74% increase year-on-year, with a net profit of 29 million yuan, reflecting a 39.89% growth [5] - The projected revenues for 2025-2027 are 364 million yuan, 503 million yuan, and 701 million yuan, with corresponding year-on-year growth rates of 30.7%, 38.2%, and 39.4% respectively [8] - The net profit attributable to the parent company is expected to be 108 million yuan, 152 million yuan, and 217 million yuan for 2025-2027, with growth rates of 36.7%, 41.3%, and 42.7% respectively [8] Valuation Metrics - The projected P/E ratios for 2025-2027 are 43x, 30x, and 21x, with PEG ratios of 1.17, 0.74, and 0.50 respectively [8]
迈普医学（301033）：业绩符合预期，收购易介拓宽天花板